Zentek Ltd. (ZTEK)
USD 0.98
(-4.85%)
USD 0.98
(-4.85%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 2.41 Million CAD | -16.97% |
| 2022 | 2.9 Million CAD | -15.45% |
| 2021 | 3.43 Million CAD | 23.22% |
| 2020 | 2.78 Million CAD | 428.46% |
| 2019 | 527.57 Thousand CAD | -18.41% |
| 2018 | 646.64 Thousand CAD | 325.32% |
| 2017 | 152.03 Thousand CAD | 82.52% |
| 2016 | 83.3 Thousand CAD | -8.5% |
| 2015 | 91.03 Thousand CAD | -49.68% |
| 2014 | 180.92 Thousand CAD | -33.57% |
| 2013 | 272.33 Thousand CAD | -45.59% |
| 2012 | 500.55 Thousand CAD | -51.69% |
| 2011 | 1.03 Million CAD | 2.43% |
| 2010 | 1.01 Million CAD | 548.91% |
| 2009 | 155.9 Thousand CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q1 | 2.54 Million CAD | 5.51% |
| 2023 Q4 | 2.41 Million CAD | 2.41% |
| 2023 Q3 | 2.35 Million CAD | -8.02% |
| 2023 FY | 2.41 Million CAD | -16.97% |
| 2023 Q1 | 4.46 Million CAD | 53.58% |
| 2023 Q2 | 2.56 Million CAD | -42.61% |
| 2022 Q2 | 2.95 Million CAD | -33.86% |
| 2022 Q3 | 3.08 Million CAD | 4.68% |
| 2022 FY | 2.9 Million CAD | -15.45% |
| 2022 Q4 | 2.9 Million CAD | -5.96% |
| 2022 Q1 | 4.46 Million CAD | 29.86% |
| 2021 Q1 | 873.85 Thousand CAD | -68.66% |
| 2021 Q3 | 1.27 Million CAD | 0.87% |
| 2021 Q4 | 3.43 Million CAD | 169.75% |
| 2021 Q2 | 1.26 Million CAD | 44.48% |
| 2021 FY | 3.43 Million CAD | 23.22% |
| 2020 Q3 | 1.02 Million CAD | 131.34% |
| 2020 Q1 | 833.69 Thousand CAD | 58.02% |
| 2020 FY | 2.78 Million CAD | 428.46% |
| 2020 Q4 | 2.78 Million CAD | 171.13% |
| 2020 Q2 | 444.49 Thousand CAD | -46.68% |
| 2019 Q3 | 548.92 Thousand CAD | 101.85% |
| 2019 Q4 | 527.57 Thousand CAD | -3.89% |
| 2019 FY | 527.57 Thousand CAD | -18.41% |
| 2019 Q1 | 407.24 Thousand CAD | -37.02% |
| 2019 Q2 | 271.94 Thousand CAD | -33.22% |
| 2018 Q2 | 580.52 Thousand CAD | 105.39% |
| 2018 Q1 | 282.65 Thousand CAD | 85.91% |
| 2018 FY | 646.64 Thousand CAD | 325.32% |
| 2018 Q4 | 646.64 Thousand CAD | 175.91% |
| 2018 Q3 | 234.36 Thousand CAD | -59.63% |
| 2017 Q4 | 152.03 Thousand CAD | -9.58% |
| 2017 FY | 152.03 Thousand CAD | 82.52% |
| 2017 Q3 | 168.13 Thousand CAD | 3.62% |
| 2017 Q2 | 162.26 Thousand CAD | 128.98% |
| 2017 Q1 | 70.86 Thousand CAD | -14.93% |
| 2016 Q2 | 233.47 Thousand CAD | 348.39% |
| 2016 Q4 | 83.3 Thousand CAD | 3.69% |
| 2016 FY | 83.3 Thousand CAD | -8.5% |
| 2016 Q3 | 80.33 Thousand CAD | -65.59% |
| 2016 Q1 | 52.06 Thousand CAD | -42.8% |
| 2015 Q4 | 91.03 Thousand CAD | -3.49% |
| 2015 FY | 91.03 Thousand CAD | -49.68% |
| 2015 Q3 | 94.33 Thousand CAD | 147.86% |
| 2015 Q2 | 38.05 Thousand CAD | -85.29% |
| 2015 Q1 | 258.79 Thousand CAD | 43.04% |
| 2014 Q1 | 195.64 Thousand CAD | -28.16% |
| 2014 Q2 | 94.47 Thousand CAD | -51.71% |
| 2014 Q4 | 180.92 Thousand CAD | -49.06% |
| 2014 FY | 180.92 Thousand CAD | -33.57% |
| 2014 Q3 | 355.15 Thousand CAD | 275.95% |
| 2013 Q4 | 272.33 Thousand CAD | -62.76% |
| 2013 Q1 | 390.57 Thousand CAD | -21.97% |
| 2013 FY | 272.33 Thousand CAD | -45.59% |
| 2013 Q2 | 1.37 Million CAD | 251.92% |
| 2013 Q3 | 731.26 Thousand CAD | -46.8% |
| 2012 Q4 | 500.55 Thousand CAD | -43.0% |
| 2012 Q3 | 878.11 Thousand CAD | -1.97% |
| 2012 Q1 | 992.42 Thousand CAD | -4.23% |
| 2012 FY | 500.55 Thousand CAD | -51.69% |
| 2012 Q2 | 895.79 Thousand CAD | -9.74% |
| 2011 Q3 | 1.24 Million CAD | -2.56% |
| 2011 Q4 | 1.03 Million CAD | -16.69% |
| 2011 FY | 1.03 Million CAD | 2.43% |
| 2011 Q1 | 1.38 Million CAD | 36.62% |
| 2011 Q2 | 1.27 Million CAD | -7.64% |
| 2010 Q3 | 337.06 Thousand CAD | 0.0% |
| 2010 FY | 1.01 Million CAD | 548.91% |
| 2010 Q4 | 1.01 Million CAD | 200.14% |
| 2009 Q4 | 155.9 Thousand CAD | 0.0% |
| 2009 FY | 155.9 Thousand CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Akoya Biosciences, Inc. | 126.59 Million USD | 98.095% |
| AngioDynamics, Inc. | 112.08 Million USD | 97.848% |
| AtriCure, Inc. | 147.76 Million USD | 98.368% |
| Avinger, Inc. | 19.97 Million USD | 87.924% |
| Azenta, Inc. | 351.22 Million USD | 99.313% |
| BioLife Solutions, Inc. | 75.05 Million USD | 96.786% |
| The Cooper Companies, Inc. | 4.1 Billion USD | 99.941% |
| Daxor Corporation | 858.75 Thousand USD | -180.853% |
| Ekso Bionics Holdings, Inc. | 16.31 Million USD | 85.214% |
| Femasys Inc. | 9.4 Million USD | 74.351% |
| GlucoTrack, Inc. | 1.7 Million USD | -41.209% |
| Harvard Bioscience, Inc. | 64.29 Million USD | 96.249% |
| Hologic, Inc. | 4.02 Billion USD | 99.94% |
| ICU Medical, Inc. | 2.25 Billion USD | 99.893% |
| Intuitive Surgical, Inc. | 2.04 Billion USD | 99.882% |
| KORU Medical Systems, Inc. | 8.1 Million USD | 70.251% |
| LeMaitre Vascular, Inc. | 48.87 Million USD | 95.066% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -265.466% |
| Innovative Eyewear, Inc. | 659.93 Thousand USD | -265.466% |
| Masimo Corporation | 1.67 Billion USD | 99.856% |
| Microbot Medical Inc. | 3.82 Million USD | 36.962% |
| Meihua International Medical Technologies Co., Ltd. | 25.07 Million USD | 90.382% |
| Merit Medical Systems, Inc. | 1.12 Billion USD | 99.785% |
| Nephros, Inc. | 3.5 Million USD | 31.149% |
| NovoCure Limited | 783.63 Million USD | 99.692% |
| NEXGEL, Inc. | 4.78 Million USD | 49.638% |
| NEXGEL, Inc. | 4.78 Million USD | 49.638% |
| Singular Genomics Systems, Inc. | 86.46 Million USD | 97.21% |
| OraSure Technologies, Inc. | 52.17 Million USD | 95.377% |
| Pro-Dex, Inc. | 23.34 Million USD | 89.668% |
| Pulse Biosciences, Inc. | 16.44 Million USD | 85.333% |
| Predictive Oncology Inc. | 6.14 Million USD | 60.754% |
| Precision Optics Corporation, Inc. | 6.84 Million USD | 64.764% |
| QuidelOrtho Corporation | 3.55 Billion USD | 99.932% |
| Repligen Corporation | 853.2 Million USD | 99.717% |
| Sanara MedTech Inc. | 29.28 Million USD | 91.764% |
| STAAR Surgical Company | 102.73 Million USD | 97.652% |
| Sharps Technology, Inc. | 3.85 Million USD | 37.436% |
| Utah Medical Products, Inc. | 7.14 Million USD | 66.244% |
| DENTSPLY SIRONA Inc. | 4.07 Billion USD | 99.941% |
| Jin Medical International Ltd. | 8.92 Million USD | 72.975% |